Carna Biosciences: Promising initial data from the phase 1b clinical trial of the next-generation BTK inhibitor AS-1763 targeting mature B-cell tumors will be presented at the European Hematology Association (EHA) in 2024.

JPX · Jun 17 14:30

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

カルナバイオサイエンス：次世代型BTK阻害剤AS-1763の成熟B細胞腫瘍を対象としたフェーズ1b臨床試験における有望な初期データを2024年欧州血液学会（EHA）で発表

Carna Biosciences: Promising initial data from the phase 1b clinical trial of the next-generation BTK inhibitor AS-1763 targeting mature B-cell tumors will be presented at the European Hematology Association (EHA) in 2024.

Risk Disclaimer

Statement